• Study eval­u­ated the benefit of isatuximab in com­bi­na­tion with standard of care in prolonging pro­gres­sion free sur­vival as com­pared to standard of care in patients with re­lapsed / re­frac­tory multiple myeloma
• First ran­dom­ized Phase 3 trial to eval­u­ate the benefit of adding a mono­clonal anti­body to poma­lido­mide and dexa­meth­a­sone for treat­ment of re­lapsed / re­frac­tory multiple myeloma
• Multiple ongoing Phase 3 studies with isatuximab, an inves­ti­ga­tional agent, in com­bi­na­tion with standard of care ther­a­pies in newly diag­nosed and re­lapsed / re­frac­tory multiple myeloma

Paris, France (Press Release) – The pivotal Phase 3 trial of isatuximab in patients with re­lapsed / re­frac­tory multiple myeloma met the pri­mary end­point of prolonging pro­gres­sion free sur­vival in patients treated with isatuximab in com­bi­na­tion with poma­lido­mide and low-dose dexa­meth­a­sone versus poma­lido­mide and low-dose dexa­meth­a­sone alone (standard of care).

Results will be sub­mitted to an upcoming medical meeting and are antic­i­pated to form the basis of regu­la­tory sub­missions planned for later this year.

"We are ex­cited by these results, …

Shanghai, China and New York, NY (Press Release) – Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a bio­pharma­ceu­tical firm engaged in the devel­op­ment of immuno­therapies for cancer and stem cell ther­a­pies for degenerative diseases, today announces the initiation of patient recruitment to sup­port the study of anti-BCMA CAR-T ther­apy targeting re­lapsed and refractory multiple myeloma in China.

"China has seen a sub­stan­tial in­­crease in the in­ci­dence of multiple myeloma. As a drug devel­op­ment com­pany, BCMA is the first of multiple assets that CBMG is ad­vanc­ing amongst our on­col­ogy pipe­line beyond our col­lab­o­ration with a …

Median over­all sur­vival of 22.0 months observed in Cohorts 1-4

Florham Park, NJ (Press Release) – Cellectar Biosciences (Nasdaq: CLRB), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on the discovery, devel­op­ment and com­mer­cial­iza­tion of drugs for the treat­ment of cancer, to­day an­nounced median over­all sur­vival (mOS) in Cohorts 1-4 of the com­pany’s on­go­ing Phase 1 clin­i­cal trial eval­u­ating CLR 131 for the treat­ment of re­lapsed / re­frac­tory (R/R) mul­ti­ple myeloma (MM). The results showed mOS of 22.0 months among 15 patients, all of whom were heavily pre­treated, averaging five prior lines of sys­temic ther­apy. Each patient in Cohorts 1-4 of this dose-escalation study re­ceived a …

• In the ELOQUENT-3 trial, treat­ment with Empliciti plus poma­lido­mide and dexa­meth­a­sone (EPd) doubled median pro­gres­sion-free sur­vival and over­all re­sponse rate versus poma­lido­mide and dexa­meth­a­sone (Pd)¹
• Low dis­con­tinu­a­tion rates due to adverse reac­tions were observed with both EPd and Pd alone¹
• Empliciti, when used in com­bi­na­tion with poma­lido­mide and dexa­meth­a­sone, can be admin­istered once monthly after first two cycles¹

Princeton, NJ (Press Release) – Bristol-Myers Squibb Com­pany (NYSE: BMY) to­day an­nounced that the U.S. Food and Drug Admin­istra­tion (FDA) approved Empliciti (elo­tuzu­mab) in­jec­tion for intra­venous use in com­bi­na­tion with poma­lido­mide and dexa­meth­a­sone (EPd) for the treat­ment of adult patients with mul­ti­ple myeloma who have re­ceived at least two prior ther­a­pies, in­­clud­ing lena­lido­mide and a pro­te­a­some in­hib­i­tor.¹ In ELOQUENT-3, a ran­dom­ized, open-label, Phase 2 trial, EPd dem­onstrated ben­e­fit in patients with re­lapsed or re­frac­tory mul­ti­ple myeloma, doubling both median pro­gres­sion-free sur­vival (PFS) …

San Diego, CA (Press Release) – Sorrento Therapeutics, Inc. (NASDAQ: SRNE), an inno­va­tive immuno­therapy com­pany, announced today that the first patients were dosed in a Phase 1 study to eval­u­ate the safety and efficacy of CD38 CAR-T ther­apy in re­lapsed or refractory multiple myeloma patients at two clin­i­cal sites – University of Pennsylvania (UPenn) in Philadelphia and Roger Williams Medical Center in Rhode Island. The CD38 CAR-T cells manu­fac­tured at both Sorrento cGMP facilities (San Diego, CA and Providence, RI) met all release specifications and were used in the study.

This study is …

Earlier this month, The Myeloma Beacon published a news article sum­marizing results of a clin­i­cal trial testing the com­bi­na­tion of nelfinavir, Velcade, and dexa­meth­a­sone as a treat­ment for re­lapsed multiple myeloma.

Nelfinavir (Viracept) is an orally admin­istered drug that was approved in the 1990s for the treat­ment of human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syn­drome (AIDS). Nel­fin­avir has not pre­vi­ously been used for the treat­ment of multiple myeloma.

Preclinical research has suggested, however, that nelfinavir might make it …

Madison, WI (Press Release) – Cellectar Biosciences (Nasdaq: CLRB), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on the discovery, devel­op­ment and com­mer­cial­iza­tion of drugs for the treat­ment of cancer, to­day up­dates interim over­all sur­vival (OS) data from the com­pany’s on­go­ing Phase 1b clin­i­cal trial eval­u­ating CLR 131 for the treat­ment of re­lapsed/refractory (R/R) mul­ti­ple myeloma (MM).

The results to date show that OS is cur­rently at 19.4 months. Cellectar con­tinues to monitor these patients and in­tends to up­date OS results as data be­come avail­able. All 15 patients from the Phase 1b, single-dose cohorts were …